Find comprehensive information on Endometrial Adenocarcinoma, also known as Uterine Cancer or Endometrial Cancer, including details on diagnosis, ICD-10 coding, clinical documentation requirements, treatment options, and healthcare resources. Learn about staging, prognosis, and best practices for medical coding related to Endometrial Adenocarcinoma for accurate clinical documentation and billing. This resource provides valuable insights for healthcare professionals, including physicians, nurses, and medical coders.
Also known as
Malignant neoplasm of corpus uteri
Cancer specifically affecting the body of the uterus.
Malignant neoplasm of isthmus uteri
Cancer affecting the narrow part of the uterus.
Malignant neoplasm of cervix uteri
Cancer affecting the lower part of the uterus that opens into the vagina.
Secondary malignant neoplasm of uterus
Cancer that has spread to the uterus from another site.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the endometrial adenocarcinoma specified as in situ?
Yes
Code C54.11, Endometrial adenocarcinoma in situ
No
Is there uterus involvement only?
When to use each related code
| Description |
|---|
| Cancer of the uterine lining. |
| Precancerous changes in the uterine lining. |
| Precancerous glandular cells in the uterine lining. |
Missing or incorrect laterality specification for endometrial adenocarcinoma impacts staging and treatment data accuracy.
Unspecified histology (e.g., NOS) for endometrial adenocarcinoma may lead to inaccurate coding, affecting quality reporting.
Accurate documentation of myometrial invasion depth is crucial for proper staging of endometrial cancer and impacts reimbursement.
Q: What are the most effective current staging guidelines for endometrial adenocarcinoma to ensure accurate prognostication and treatment planning?
A: Accurate staging of endometrial adenocarcinoma is crucial for prognostication and personalized treatment planning. The current gold standard is the 2009 FIGO staging system, which incorporates surgical findings, including the depth of myometrial invasion, cervical stromal involvement, and the presence of extrauterine spread to adnexa, lymph nodes, and distant sites. This system helps clinicians stratify patients into distinct risk categories and guide treatment decisions, ranging from surgery alone for early-stage disease to adjuvant chemotherapy and radiation for advanced stages. Consider implementing a standardized staging protocol in your practice to ensure consistent and accurate application of the FIGO guidelines. Explore how molecular profiling can further refine risk stratification and personalize treatment strategies for endometrial adenocarcinoma.
Q: How can I differentiate between Type I and Type II endometrial adenocarcinoma in my clinical practice, considering their distinct molecular profiles and prognostic implications?
A: Distinguishing between Type I and Type II endometrial adenocarcinoma is essential for optimal patient management due to their differing molecular profiles and prognoses. Type I, often associated with estrogen excess, typically exhibits endometrioid histology, lower grade, and better prognosis. Type II, less common but more aggressive, often presents with serous or clear cell histology, higher grade, and tends to have deeper myometrial invasion and lymphatic spread. While histopathology remains the primary diagnostic tool, immunohistochemistry can be valuable in challenging cases. Explore how incorporating molecular markers, such as POLE mutations and p53 overexpression, can further enhance diagnostic accuracy and guide treatment selection for these distinct subtypes. Learn more about the evolving role of molecular classification in refining our understanding and management of endometrial adenocarcinoma.
Patient presents with complaints consistent with possible endometrial adenocarcinoma, also known as uterine cancer or endometrial cancer. Key symptoms include abnormal uterine bleeding, specifically postmenopausal bleeding or irregular periods, along with pelvic pain or pressure. Differential diagnoses considered include endometrial hyperplasia, uterine fibroids, and other gynecologic malignancies. Physical examination revealed normal external genitalia. Bimanual exam revealed a slightly enlarged uterus. Pelvic ultrasound was performed and demonstrated endometrial thickening, prompting endometrial biopsy for histopathological evaluation. Biopsy results confirmed the diagnosis of endometrial adenocarcinoma, grade [Insert Grade]. Staging workup, including CT scan of the abdomen and pelvis, chest x-ray, and CA-125 levels, is planned to determine the extent of disease. The patient was counseled regarding treatment options, including total hysterectomy with bilateral salpingo-oophorectomy, potentially followed by adjuvant radiation therapy or chemotherapy depending on final staging. Risks and benefits of each treatment modality were discussed. Patient understands the diagnosis and plan and will schedule a follow-up appointment to discuss surgical planning and answer any further questions. The patient's medical history includes [relevant medical history such as hypertension, diabetes, obesity, or family history of cancer]. Current medications include [list current medications]. Allergies include [list any allergies]. ICD-10 code C54.1 is recorded for endometrial adenocarcinoma. Further coding will be completed upon completion of staging and treatment.